The Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)1 of the relative effectiveness of first (FGA)- and second (SGA)-generation antipsychotic treatments of schizophrenia reports negative findings, concluding that “there is no disadvantage across 1 year . . . in using FGAs. . . . ”1(p1079) In one commentary,2 Lieberman calls the findings of CUtLASS and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study “virtually identical,” clearly referring to what he calls the “sobering”2(p1071) conclusion that “these studies found few differences in effectiveness between first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). . . . ”2(p1069) In another commentary,3 Rosenheck writes that CUtLASS “echoes” CATIE, which “similarly, found no significant differences in time to all-cause discontinuation, the primary outcome. . . . ”2(p1075)
Mintz J, Kopelowicz A. CUtLASS Confirms CATIE. Arch Gen Psychiatry. 2007;64(8):978. doi:10.1001/archpsyc.64.8.978-a
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: